ISPOR 8th Annual European Congress
6-8 November 2005, Palazzo Degli Affari, Florence, Italy

S U B M I S S I O N  T I M E L I N E

Access to
Online Submission System

15 March 2005

Abstract Submission Deadline:
20 June 2005
 

Acceptance
Notification
2 August 2005

RESEARCH ABSTRACTS SUBMISSION INFORMATION AND INSTRUCTIONS

GENERAL INFORMATION:

Abstract submissions are invited for CONTRIBUTED RESEARCH, CONTRIBUTED WORKSHOPS, AND CONTRIBUTED ISSUES PANELS
  • ALL ABSTRACTS MUST BE SUBMITTED THROUGH ISPOR’S ONLINE ABSTRACT SYSTEM VIA WWW.ISPOR.ORG.
  • All abstract submissions and presentations must be in English.
  • Annual Congress registration is required for all presenters.
  • Expenses associated with the submission and presentation of an abstract are the responsibility of the presenter.
  • The presenters of research are required to disclose financial support. Abstract review will NOT be based on this information.
  • The abstract, excluding title and author information, should be no longer than 300 words.
  • The use of tables and graphs in your abstract submission is not allowed.
  •  ALL ABSTRACTS MUST BE SUBMITTED BY 20 JUNE 2005.

CONTRIBUTED RESEARCH SUBMISSION INFORMATION

GENERAL INFORMATION:

  • Research abstracts (except Methods & Concept abstracts) must be organized as follows: OBJECTIVES: METHODS: RESULTS: CONCLUSIONS:
  • Research on all diseases is considered. Study methods include, but are not limited to, conjoint analysis, large database analysis, quasi-experimental analysis, literature or record review, modeling, naturalistic (observational) studies, randomized clinical trials and surveys.
  • Research on all health care interventions is considered including drugs, behavioral modification, disease prevention, gene therapy, medical device, screening, diagnostic procedures, dietary, health education, radiation therapy, and surgical procedures.
  • Reviews or methods papers are also considered as research abstracts.
  • Any human experimentation must conform to the principles of the Declaration of Helsinki of the World Medical Association (Clin Res.1992; 40: 653-660).
  • Accepted abstracts will be published AS SUBMITTED in Value in Health and distributed at the Annual Congress. Changes to abstracts will not be accepted after the Submission Deadline, therefore, they should be carefully written and edited prior to submission.
  • Abstracts accepted at a prior ISPOR meeting are NOT accepted.
  • Research RESULTS must be included for an abstract to be considered for presentation.
  • See Research Abstract Example

TOPICS FOR RESEARCH SUBMISSIONS:

Research submissions on the following topics are considered:

  • Clinical Outcomes Studies (COS)
  • Cost Studies (CS)
  • Patient Reported Outcomes: QoL, PP, WTP, Utilities, Work/Patient/Treatment Satisfaction & Compliance/Persistence
  • Health Care Use & Policy Studies (HP)
  • Methods and Concepts (MC)
     
CLINICAL OUTCOMES STUDIES (COS)

HEALTH CARE USE & POLICY STUDIES (HP)

Efficacy/Effectiveness (EE)
Co-morbidities (CM)
Adverse Events (SE)
Diagnosis (D)
Survival (S)
Risk Factors (RF)
Prevalence/Incidence (PV)  

Consumer Role in Health Care (CRH)
Diagnosis Related Group (DRG)
Disease Management (DISM)
Drug or Devices & Health Policy (DHP)
Drug Use (DU)
Equity and Access (EA)
Formulary Development/PharmacyBenefit (FD)
Health Care Reimbursement (HR)
Health Care Expenditure (HE)
Health Care Management (including pharmaceutical care) (HM) Health Care Information (HI)
Health Care Research (HCR)
Medical Devices/Diagnostics (MD)
Patient/Provider/Payer/Regulator/Researcher Education (PE)
Patient Registries (PR)
Pharmacogenomics (PG)
Post Marketing Studies (PMS)
Prescribing Behavior (PB)
Productivity/Work Performance (PWP)
Quality of Care/Quality Improvement (QC)
Regulation of Health Care Sector (RHS)
Treatment Patterns / Guidelines (TPG)

COST STUDIES (CS)

Budget Impact (BI)
Cost-Benefit Analysis (CB)
Cost-Effectiveness Analysis (CE)
Cost-Efficiency Analysis (CEE)
Cost-consequence (CN)
Cost-Minimization Analysis (CM) 
Cost-Utility Analysis (CU)
Cost of Illness (CoI)
Cost of Treatment (CoT)
Cost Comparison (CC)
Productivity/Work Performance (PI)
Resource Use (RU)

PATIENT REPORTED OUTCOMES: QoL, PP, WTP, Utilities, Work/Patient/Treatment Satisfaction & Compliance/Persistence

METHODS AND CONCEPTS (MC)

Quality-of-Life (hrQoL)
Health Status (HS)
Patient Reported Outcomes (PRO)
Willingness-to-Pay (WTP)
Patient Preference (PP)
Patient Satisfaction (PS)
Treatment Satisfaction (TS)
Adherence/Compliance/Persistence (AD)

Clinical Outcomes Studies (CO)
Costs Studies including CE/CB/CU, resources use, and productivity (CS)
Database Studies & Management (DM) 
Study & Methods Design-General (SD)
Modeling Studies (MS)
Patient Registry (PR)
Quality of Life / PRO / Utility / Preference Studies (QOL) 

DISEASE/DISORDER FOR RESEARCH SUBMISSIONS:
When submitting your abstract, you must select the DISEASE/ DISORDER that best describes your research. If no disease or multiple diseases apply to your abstract, select Multiple Diseases/No Specific Disease. If the disease is not listed, select Other.

- Allergy
- Arthritis-Osteoarthritis
- Arthritis-Rheumatoid Arthritis
- Arthritis-Other
- Asthma
- Cancer
- Cardiovascular Disease-Angina /Ischemia/Coronary Syndrome
- Cardiovascular Disease-Angioplasty
- Cardiovascular Disease-Arrhythmia
- Cardiovascular Disease-Atrial Fibrillation
- Cardiovascular Disease-Congestive Heart Failure / Heart Failure
- Cardiovascular Disease-Coronary Artery Disease
- Cardiovascular Disease-Hypercholesterolemia
- Cardiovascular Disease-Hypertension
- Cardiovascular Disease-Left Ventricular Dysfunction (LVD)
- Cardiovascular Disease-Myocardial Infarction
- Cardiovascular Disease-Peripheral Arterial Disease
- Cardiovascular Disease-Stents
- Cardiovascular Disease-Thrombosis including DVT
- Cardiovascular Disease-Multiple disorders
- Cardiovascular Disease-Other
- Diabetes
- Endocrine Disorders-other (Pituitary Gland/Thyroid)
- Eye
- Ear
- GI Disorders (including Dyspepsia, GERD, Irritable Bowel, Liver, Ulcers)
- Health, Women’s
- Health, Men’s
- Health, Children’s
- Health, Elderly
- Hematological Disorders
- Infection (including leg ulcers & bronchitis)
- Infection-HIV
- Infection-influenza
- Infection-vaccine
- Mental Health-Alcoholism / Drug Abuse
- Mental Health-Anxiety
- Mental Health-Attention Deficit Disorder
- Mental Health-Bi-Polar Disorder
- Mental Health-Depression
- Mental Health-Dementia
- Mental Health-Obsessive Compulsive Disorder
- Mental Health-Psychosis
- Mental Health-Schizophrenia
- Mental Health-Other
- Muscular-skeletal Disorders including Carpal Tunnel Syndrome
- Neurological Disorders-Alzheimer’s Disease
- Neurological Disorders-Epilepsy
- Neurological Disorders-Cystic Fibrosis
- Neurological Disorders-Migraine
- Neurological Disorders-Multiple Sclerosis
- Neurological Disorders-Parkinson’s Disease
- Neurological Disorders-Sleep Disorders
- Neurological Disorders-Other
- Obesity
- Osteoporosis (inluding falls, injuries, bone disorders)
- Pain
- Respiratory Disorders (including Chronic Obstructive Pulmonary Disease [COPD])
- Skin (including hair loss)
- Smoking
- Stroke
- Urinary/Kidney (including Renal Disease, Irritable Bladder Syndrome)
- Surgery
- Multiple Diseases/No Specific Disease

CRITERIA FOR EVALUATION OF RESEARCH ABSTRACTS:

Quality Of Study Criteria: (For Research Study Abstracts)

Note:
For studies involving data collection or analysis, the abstract will be REJECTED if RESULTS are NOT included.

  1. Research design is appropriate and transparent.
  2. Data sources are appropriate and transparent.
  3. Data analyses are appropriate and transparent.
  4. Results ARE INCLUDED and are transparent and comprehensible.
  5. Conclusions are consistent with the results.

Quality Of  Methods And Concept: (For Methods and Concepts Abstracts)

  1. Approach to method and/or concept is apparent.
  2. Approach represents advancement or is innovative.
  3. Practical implications/recommendations provided.
  4. Papers do NOT need to be organized: Objectives: Methods: Results: Conclusions:

Quality of the Abstract Presentation Criteria:

  1. Objectives/research questions are clearly stated and objectives are addressed.
  2. Factual information is kept separate from interpretations or implications / unbiased presentation.
  3. Implications/results, as presented, are easy to understand.

Impact Factor & Public Awareness

  1. Impact Factor - The reviewer will rate the abstract on a scale of 1 - 5 (1 =low impact ; 5=very high impact ) if the study results described in the abstract will have an impact on health care decisions by health care decision-makers and/or patients.
  2. Public Awareness - The reviewer will indicate (yes, no, or no comment) whether the results of this study will contribute to the health care improvement of society and the public should be made aware of the study results reported in this abstract.

ABSTRACT REVIEW PROCESS AND NOTIFICATION OF AUTHORS:

  • All research abstracts will be peer reviewed by at least 3-blinded reviewers.
  • Research abstracts will be evaluated based on the criteria listed below.
  • All presenters will be notified by email by 2 August, 2005.

PRESENTATION OF RESEARCH ABSTRACTS:

PODIUM PRESENTATIONS

  • All oral presentations will be programmed into 15-minute time slots. You will have 12 minutes for presentation and 3 minutes for questions and discussion. It is important that you not exceed 15 minutes. Financial support for the research must be presented at the beginning of the presentation.
  • Audiovisual equipment: An LCD projector and laptop computer will be provided. Slide projection or overhead transparency projection are not allowed.
  • YOU ARE REQUIRED TO BRING AT LEAST 100 HANDOUTS OF YOUR PRESENTATION MATERIAL.
  • Presenter MUST email electronic slides NOT LESS THAN 10 DAYS in advance of the Congress to the ISPOR office at podium@ispor.org.

POSTER PRESENTATIONS

  • At least one author must be present during the Author Discussion Hour given below

    Poster Presentation Timetable:
    Session I Poster Presentations Session II Poster Presentations
    Poster Set-up:
    Poster Display Hours:
    Author Discussion Hour:
    Dismantle:
    Sun, 6 Nov 11:30-12:00
    Sun, 6 Nov 12:00-Mon, 7 Nov 14:00
    Sun, 6 Nov 18:00-19:00
    Mon, 7 Nov 19:30
    Poster Set-up:
    Poster Display Hours:
    Author Discussion Hour:
    Dismantle:
    Mon, 7 Nov 16:30- 17:00
    Mon, 7 Nov 16:30- 17:00
    Mon, 7 Nov 18:00- 19:00
    Tue, 8 Nov 17:00- 17:30

  • The abstract title and authors must be placed at the top of the board, and the lettering must be at least 1 inch high. A copy of the abstract, typed in large print, must be placed in the upper left hand corner of the board. Subtitles should correspond to those used in your abstract submission. Illustrations, charts, tables, lettering, and drawings must be readable from distances of at least three feet. Financial support must be displayed at the lower right hand corner of the board.
     
  • Mounting materials will be available on-site.
     
  • YOU ARE REQUIRED TO BRING AT LEAST 100 HANDOUTS OF YOUR PRESENTATION MATERIAL.

CONTRIBUTED WORKSHOP SUBMISSION INFORMATION

GENERAL INFORMATION

  • Contributed Workshop are designed to share novel and innovative experiences in either the conduct of pharmacoeconomics and outcomes research studies or the interpretation and use of pharmacoeconomics outcomes information in health care policy development.
  • Workshop submissions must be organized as follows: Workshop Purpose:  Description:
  • Accepted Workshop Submissions are published AS SUBMITTED in the Congress Final Program.
  • See workshop example

TOPICS FOR WORKSHOP SUBMISSIONS:
Workshop submissions are accepted on the following TOPICS:

Workshop submissions are accepted on the following TOPICS:
  • Clinical study methodology issues including pharmacoepidemiology (COS)
  • Cost study methodology issues (CS)
  • Quality of life study methodology issues including patient reported outcomes (QOL)
  • Preference-based studies methodology issues including utility studies (PS)
  • Drug/device coverage research issues (FS)
  • Health care policy development issues using outcomes research (HP)
  • Risk assessment/risk management issues (RK)
  • Compliance issues (CMP)
  • Patient registries development issues (PR)

WORKSHOP REVIEW PROCESS AND NOTIFICATION OF AUTHORS:

  • All contributed workshops are peer reviewed by at least 3 reviewers (not blinded).
  • Contributed Workshop submissions will be evaluated based on relevance and completeness of information presented based on the Contributed Workshop Criteria given below.
  • Authors will be notified no later than 20 July, 2005, regarding abstract acceptance and placement in the Annual Congress program.

CRITERIA FOR EVALUATION OF CONTRIBUTED WORKSHOPS:
Workshop acceptance is based on the quality of the submission and the topic for discussion

  • The workshop objective(s) are clearly stated.
  • The objective(s) can be achieved in the 60 minutes allotted for this workshop.
  • The information / issue(s) presented are novel or innovative.
  • The information / issue(s) presented is valuable to the pharmacoeconomic &
    outcomes researcher or the health care decision-maker.
  • There is an audience interactive element in the workshop.
  • The workshop does NOT appear to be advertising the presenter’s company’s services or products.
  • PLEASE NOTE: Abstracts accepted at prior meetings will NOT be accepted

PRESENTATION OF CONTRIBUTED WORKSHOP ABSTRACTS:

  • All workshops will be programmed into 60-minute time periods.
  • A single presenter or multiple presenters may present workshops.
  • A minimum of 15 minutes of structured audience participation is required.
  • Visual equipment: an LCD projector and screen will be provided in each room. However, YOU MUST BRING YOUR OWN LAPTOP COMPUTER.

CONTRIBUTED ISSUE PANEL SUBMISSION INFORMATION

GENERAL INFORMATION

Contributed Issues Panels are designed to stimulate real debate on new or controversial issues in health economic/pharmacoeconomic and outcomes research or use of outcomes research in health care decision-making.

  • An Issue Panel is composed of a moderator and 1 to 2 panelists.
  • To assure lively debate, panelists and/or moderator should be from different institutions and/or work environments representing different perspectives to the debate.
  • Panelists should present distinct views about the topic
  • Issue Panel submissions abstracts must be organized as follows:
    • Title: Full title of your Issue Panel (showing the debate issue in the title is recommended)
    • Moderator and/or Contact Person: Name, degrees, position, and full contact information for the Moderator of the Issue Panel
    • Panelists: Names, degrees, positions, and full contact information for the Issue Panelists. A maximum of three panelists is suggested. Each panelist should represent a different point of view.
    • Issue: A clear definition of the issue should be described indicating the perspectives to be presented (with panelists named for each perspective)
    • Overview: Background information on the issue(s) should be included.
  • Accepted abstracts are published AS SUBMITTED in the Congress Final Program.
  • See Issue Panel Example

TOPICS FOR ISSUE PANEL SUBMISSION
Issue Panel submissions are accepted on (but not excluded to) the following topics:

  • Pharmacoeconomic / Health Economic Study Methodology Issues (PMI)
  • Quality of Life / Patient-Reported Outcomes Study Methodology Issues (QMI)
  • Utility (Preference-based) Study Methodology Issues (UMI)
  • Clinical Outcomes (treatment guidelines) (COS)
  • Health Policy (HP)
  • Health Care Reimbursement / Coverage Issues (RC)
  • Risk Assessment Study Issues (RK)
  • Use of Health Economic/ Pharmacoeconomic Information By Decision-Makers (USE)

ISSUE PANEL SUBMISSION REVIEW PROCESS AND NOTIFICATION OF AUTHORS:

  • Contributed Issue Panel submissions are reviewed by at least 3 reviewers and the Issue Panel Chair(s)
  • Proposals will be evaluated based on topic, relevance to Congress theme and completeness of information presented based on the criteria given above
  • Authors will be notified no later than 20 July 2005, regarding abstract acceptance and placement in the Annual Congress program.

CRITERIA FOR EVALUATION OF THE CONTRIBUTED ISSUE PANEL

  • Is the issue clearly defined?
  • Is more than 1 perspective identified?
  • Is the background information (included in the overview) clear and concise?
  • Is there time allotted for audience discussion and debate?
  • PLEASE NOTE: Abstracts accepted at prior meetings will NOT be accepted

PRESENTATION OF CONTRIBUTED ISSUE PANELS

  • All Issues Panels will be 60 minutes.
  • 20-30 minutes of audience participation is required
  • An LCD projector screen and microphones will be provided. However, YOU MUST BRING YOUR OWN LAPTOP COMPUTER.

Online Abstracts Submission System
 


8th Annual European Congress Main Page

 

Contact ISPOR @ info@ispor.org  |  View Legal Disclaimer
©2008 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.
 
Website design by Eagle Systems USA, Inc.